ESPR vs. RDUS, OMER, PAHC, CARA, CALT, PTGX, TARO, EWTX, ARDX, and GPCR
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Radius Recycling (RDUS), Omeros (OMER), Phibro Animal Health (PAHC), Cara Therapeutics (CARA), Calliditas Therapeutics AB (publ) (CALT), Protagonist Therapeutics (PTGX), Taro Pharmaceutical Industries (TARO), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), and Structure Therapeutics (GPCR).
Esperion Therapeutics (NASDAQ:ESPR) and Radius Recycling (NASDAQ:RDUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
In the previous week, Esperion Therapeutics had 1 more articles in the media than Radius Recycling. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Radius Recycling. Radius Recycling's average media sentiment score of 1.69 beat Esperion Therapeutics' score of 1.53 indicating that Radius Recycling is being referred to more favorably in the news media.
Esperion Therapeutics received 258 more outperform votes than Radius Recycling when rated by MarketBeat users. Likewise, 69.92% of users gave Esperion Therapeutics an outperform vote while only 54.34% of users gave Radius Recycling an outperform vote.
Radius Recycling has higher revenue and earnings than Esperion Therapeutics. Radius Recycling is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
Radius Recycling has a net margin of -2.28% compared to Esperion Therapeutics' net margin of -37.65%. Esperion Therapeutics' return on equity of 0.00% beat Radius Recycling's return on equity.
Esperion Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Radius Recycling has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Radius Recycling shares are owned by institutional investors. 1.0% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Radius Recycling shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Esperion Therapeutics presently has a consensus price target of $9.33, suggesting a potential upside of 229.80%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Radius Recycling.
Summary
Esperion Therapeutics beats Radius Recycling on 10 of the 18 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Esperion Therapeutics Competitors List
Related Companies and Tools
